Abstract: The present invention provides a lipid nano-particles, which allow nucleic acids to be easily introduced into cells, comprising a cationic lipid represented by formula (I) (wherein: R1 and R2 are, the same or different, alkenyl, etc, and X3 is absent or is alkyl, etc, X1 and X2 are hydrogen atoms, or are combined together to form a single bond or alkylene, and Y1 is absent or anion, L1 is a single bond, etc, R3 is alkyl, etc), and the like.

Abstract: The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same.

Abstract: The present invention provides targeting lipids of structure L100-linker-L101??(CI), where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.

Abstract: Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described.

Abstract: The invention provides nucleic acid structures of controlled size and shape, comprised of a plurality of oligonucleotides, and methods for their synthesis. The structures are formed, at least in part, by the self-assembly of single stranded oligonucleotides. The location of each oligonucleotide in the resultant structure is known. Accordingly, the structures may be modified with specificity.

Abstract: Compositions comprising one or more compounds expressed by fetal tissues for modulating skin conditions, methods of identifying the compounds, and methods of making and using the compounds are provided.

Abstract: The invention relates to methods of preparing a bone matrix solution, a bone matrix implant, and variants thereof. The invention also relates to methods of cell culture using the same. The invention further relates to bone matrix scaffolds comprising one or more bone matrix nanofibers, methods of preparing, and methods of use thereof. The invention also relates to methods of culturing cells and promoting differentiation of stem cells using the same.

Abstract: The specification relates to an internal structured self assembled liposome (ISSAL), containing a nuclear core molecule or complex including a first affinity enhancing molecule; and a phospholipid-affinity enhancing complex having a phospholipid coupled to second affinity enhancing molecule, wherein the second affinity enhancing molecule couples to the first affinity enhancing molecule. The ISSAL's can be used in, for example and without limitation, the field of drug delivery, vaccination, imaging contrast agents, and nanotechnology, in which liposomes of ordered, self-assembling structure are employed to deliver soluble or insoluble molecules to any sub-cellular address.

Abstract: A coated seed obtained by coating a seed with a coating material containing an inorganic mineral powder and a thermosetting resin powder having an average particle diameter of 10 to 200 ?m, wherein the thermosetting resin powder is a thermosetting resin powder obtained by aggregating a powdery pesticide with a thermosetting resin has an excellent quality.

Abstract: An aqueous adjuvant concentrate can be prepared using a formulation including: a. from about 15 to about 45% by weight of a potassium salt chosen among di-potassium phosphate, potassium sulfate, potassium nitrate, tri-potassium citrate, potassium salts of ethylenediaminetetraacetic acid and mixture thereof; b. from about 0.5 to about 6% by weight of at least one surfactant and c. from about 3 to about 9% by weight of a hydroxypropyl tamarind gum; wherein a, b, and c are dissolved into the aqueous adjuvant. The aqueous adjuvant can include other compounds such as ah herbicide.

Abstract: An object of the present invention is to provide a liposome which is excellent in intrapulmonary delivery controllability of drugs or genes and is suited for pulmonary administration. By modifying the surface of a liposome using a terminal hydrophobized polyvinyl alcohol and/or chitosan, retention of drugs or genes encapsulated in the liposome on the surface of lung tissue and transfer of drugs or genes into lung tissue can be properly modulated, and thus in vivo behavior can be controlled.

Abstract: The invention relates to active eutectic mixtures of butyl methoxydibenzoylmethane, isopropyl myristate and optionally 12-hydroxystearic acid, personal care products comprising such active eutectic mixtures, a method for preparing such personal care compositions and a method of applying to human skin such personal care compositions.

Abstract: The present invention provides, among other things, a particle which includes a core comprised of self-assembled one or more nucleic acid molecules, the core being characterized by an ability to adopt at least two configurations: a first configuration having a first greatest dimension greater than 2 ?m and; a second configuration having a second greatest dimension less than 500 nm, wherein addition of a film coating converts the core from its first configuration to its second configuration. Methods of making and using of provided particles are also disclosed.

Abstract: The invention relates to engineered CRISPR/Cas9 systems for genomic modification and regulation of gene expression in mammalian cells. The specification describes the design and validation of polynucleotides encoding the Streptococcus pyogenes (S. pyogenes) Cas9 gene and protein and variants of that protein, where the nucleotide sequence has been optimized for expression in mammalian cells, and also modified by fused sequences that enhance various aspects of the CRISPR/Cas system. The specification also describes systems for RNA-guided genome engineering and gene regulation in mammalian cells, including human cells.

Abstract: The present invention relates generally to a population of cells genetically modified to produce insulin in a glucose responsive manner and uses thereof. More particularly, the present invention relates to a population of cells genetically modified to produce insulin in response to physiologically relevant levels of glucose and uses thereof. The cells of the present invention are useful in a wide variety of applications, in particular in the context of therapeutic and prophylactic regimes directed to the treatment of diabetes and/or the amelioration of symptoms associated with diabetes, based on the transplantation of the cells of the present invention into mammals requiring treatment. Also facilitated is the design of in vitro based screening systems for testing the therapeutic effectiveness and/or toxicity of potential adjunctive treatment regimes.

Abstract: There is provided a powder composition comprising a collection of particles (I) having median particle diameter of 10 micrometers to 200 micrometers, wherein each of said particles (I) comprises (a) a covering of a fatty compound having melting point of 50° C. to 110° C. and (b) one or more inner particles (II) comprising one or more complex that contains a cyclopropene compound molecule or a portion of a cyclopropene compound molecule encapsulated in a molecule of a molecular encapsulating agent. Also provided is a slurry comprising water and such a powder. Also provided is a method of contacting plants or plant parts with such a slurry.

Abstract: Provided is a biocomposite including cells, a genetic construction, and a scaffold and a method for repairing tissue and organs in mammalians with the biocomposite. The interaction of the components of the biocomposite provides a complex effect on reparative regeneration processes. Also provided is a method for administration of gene-cellular therapeutic constructions to a recipient which can be used in medicine and veterinary to provide reparative processes. After administering the biocomposite to a recipient, the scaffold structure releases the nucleic acids which enter into the cells of a recipient bed and cells of the transplanted product. The nucleic acids are expressed, which results in the increased concentration of a target product responsible for reparative processes.

Abstract: The present invention relates to a cosmetic tissue comprising microemulsion particles, and to a production method for same and method of using same. The present invention provides a cosmetic tissue to which is securely attached a dried composition comprising microemulsion particles of no more than 5,000 nm. Also, the present invention provides a production method for cosmetic tissue comprising: a first step of obtaining a composition comprising microemulsion particles of no more than 5,000 nm; a second step of coating the composition onto a tissue substrate; and a third step of drying the composition, and the present invention provides a method of using same. According to the present invention, after the skin has been cleaned, removal of the remaining water fraction and coating of a dermatological beauty composition are carried out in one go, thereby allowing easy-to-use and effective cosmetic enhancement to the skin.

Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.

Abstract: Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source. Also provided are methods of optically inducing nuclear translocation of a fusion protein containing a mammalian estrogen receptor ligand binding domain in a eukaryotic cell and methods of optically inducing recombination in a eukaryotic cell that include contacting a eukaryotic cell with at least one of these compositions. Also provided are methods of treating breast cancer in a subject that include administering a photoactivatable caged tamoxifen or tamoxifen derivative molecule to a subject having breast cancer.